SEPN - Septerna, Inc.
Region: US
Website: septerna.com
Employees: 0
IPO year: 2024
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G prote
Read moreSepterna, Inc. (SEPN): Among Top Insider Purchases Last Month
We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical agenda? […]
Read moreSepterna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently
We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against the other stocks. We previously covered 10 stocks with at least $20 million in insider spending recently. Trump administration’s tariffs on […]
Read more